According to a new report by Quince Market Insights, the global migraine therapeutics market is estimated to be valued at US$ 7 billion in the year 2025, growing at a CAGR of 15.2% in the period 2016 to 2025.
Get free sample copy of this report @ https://bit.ly/3kqxA2B
Key Factors Impacting Market Growth
- Prevalence of migraine
- Stressful Life
Companies Covered: Eli Lilly & Company, Teva Pharmaceutical Industries, Alder Biopharmaceuticals, Amgen Inc., AbbVie Inc., Pfizer Inc.
Market Segmentation:
By Drugs:
- Triptan
- CGRP
- Others
Get free PDF of this report @ https://bit.ly/3nSGNTD
The Global Asthma and COPD Drugs Market is expected to reach USD 62.32 billion by 2028 from USD 43.19 billion in 2019, growing at a CAGR of 4.2% during the forecast period.
Increasing asthma and COPD incidence and prevalence, advances in technology, and the rising senescent population is expected to propel the asthma and COPD drugs market during the forecast period.Get free sample copy of this report @ https://bit.ly/3m3lbRH Key Developments in the Asthma and COPD Drugs Market:In 2016, GlaxoSmithKline bought global rights to an experimental drug from Johnson and Johnson, raising its bet on a new generation of biotech medicines for severe asthma.
The British drugmaker launched Nucala, its first injectable biological asthma drug, and is looking for additional treatments to help more patients who are still struggling with breathing problems.In 2018, AstraZeneca unloaded rights to Alvesco (ciclesonide) to treat persistent asthma, and Omnaris and Zetonna (ciclesonide) to treat nasal symptoms associated with rhinitis.
The company indicates that the rights cover markets outside the United States and the US royalties for the drugs.
Covis already commercializes the three drugs in the US, but upon closing, it will own them.In 2015, AstraZeneca announced that it has entered into a definitive agreement to acquire the core respiratory business of Takeda Pharmaceutical Company Limited (“Takeda”).
The deal will include the expansion of rights to roflumilast (marketed as Daliresp in the US and Texas in other countries), the only approved oral PDE4 inhibitor for the treatment of chronic obstructive pulmonary disease (COPD).
According MarketsandMarkets Research – The Rat Model Market is expected to reach USD 588.9 million, at a CAGR of 8.7%.Application of Rat Model in Detailed:Rat model applications in various therapeutic indications such as toxicology, oncology, diabetes, neurology, immunology and infectious diseases, and others (rare disease, cardiovascular, metabolic disease, hematopoiesis, and regenerative medicines) coupled with the increase in R activities carried out by pharmaceutical and biotechnology companies drive the growth of rat model marketDIABETES:Rats are considered to be excellent experimental models for understanding the complex genetic basis of diseases such as diabetes.
However, it is quite difficult to carry out research studies in human beings, owing to problems such as genetic heterogeneity and lack of controlled lifestyles.
Rat models act as suitable models to study specific genetic mutations and to understand the function of genes on a homogeneous genetic background.Browse 132 market data tables and 47 figures spread through 253 pages and in-depth TOC | Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=76036494Market Segmentation in Depth:On the basis of type, the rat model market is segmented into outbred rats, inbred rats, knockout/genetically engineered rats, hybrid/congenic rats, conditioned/surgically modified rats, and immunodeficient rats model.
Knockout/genetically engineered rats segment is expected to grow at the highest CAGR during the forecast period.
The high growth rate of knockout/genetically engineered rats segment can be attributed to the use of this type of rat model to carry out researches on disease such as oncology, obesity, heart disease, diabetes, arthritis, drug abuse, anxiety, aging, and Parkinson’s.On the basis of services, the rat model market is segmented into breeding, cryopreservation, quarantine, rederivation, model in-licensing, genetic testing, and others such as surgical services, line rescue services, and in vivo pharmacology services.
The cryopreservation segment is estimated grow at the highest CAGR during the forecast period, as this segment help in obtaining the genetic material of rats even after the reproductive lifespan of these rats is over.